CasNo.380843-75-4,Bosutinib API with high Assay in stock CAS: 380843-75-4,(380843-75-4) Suppliers

1 Kilogram	FOB Price: USD 1000.0000

Min.Order :1 Kilogram
Purity: >98%
Payment Terms : L/C,D/A,D/P,T/T,

Keywords

380843-75-4 Bosutinib high quality Bosutinib

Quick Details

Appearance:Off-White Powder
Application:For lab research use only
PackAge:1kg/ bag, 25kg/drum
ProductionCapacity:10|Kilogram|Month
Storage:Keep in a cool & dry place
Transportation:By air/sea

Superiority:

opbatt Chemical Co. Ltd., Established in 2019, located in Shenzhen, Guangdong Province, is a Manufacturer and Trading company which specialized in fine chemicals like Pharmaceutical Reference Standards, Stable Isotopes, APIs and Intermediates. Our Stable Isotopes product line including 2H Labelled APIs, Reagents and Intermediates, 13C Labelled Substance, 15N Labelled Substance and 18O Labelled Substance.

We own a number of Senior pharmaceutical synthetic engineer, analysis engineer and analytical testing instrument. It make us have more than 1700 varieties compouds with high purity in stock in a short time.

We can provide you not only stock items, but also Custom Synthesis Service.

All of our Reference Standards, Stable Isotopes with COA, HPLC/GC, HNMR, qNMR, MS Spectrum.

Contact us at 0086-18923794376 or email us at yehh@topbatt.net, 24/7 stand by for you.

After-sales issues will be settled in 24 hours.

Details:

Product Name: Bosutinib

Chemical Name: 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Molecular Formula: C₂₆H₂₉Cl₂N₅O₃

Molecular Weight: 530.45

CAS#: 380843-75-4

Packing: 1kg/ bag, 25kg/drum

Assay: >98%

Appearence: Off-White Powder

Price: Negotiable

Available Document: COA, MSDS, TSE/BSE, NMR, HPLC, DMF

Payment Term: T/T, L/C, O/A, ect.

Shipment: Package will dispatched in 7-15 days(According to the date of payment) by air.

Trade Term: EXW, FOB, CFR, DDU, DDP, ect.

Bosutinib is a Bcr-Abl kinase inhibitor for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Compared to other tyrosine kinase inhibitors, it has a more favourable hematologic toxicity profile. FDA approved on September 4, 2012